Pacira BioSciences (PCRX) Scheduled to Post Quarterly Earnings on Tuesday

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Pacira BioSciences to post earnings of $0.64 per share for the quarter. Pacira BioSciences has set its FY 2024 guidance at EPS.Persons that wish to listen to the company's earnings conference call can do so using this link.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The company reported $0.71 earnings per share for the quarter, hitting analysts' consensus estimates of $0.71. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. The company had revenue of $181.24 million during the quarter, compared to analyst estimates of $180.60 million. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pacira BioSciences Stock Up 2.7 %

NASDAQ:PCRX traded up $0.70 during mid-day trading on Wednesday, reaching $26.95. The company's stock had a trading volume of 449,862 shares, compared to its average volume of 489,742. Pacira BioSciences has a 1 year low of $25.33 and a 1 year high of $47.01. The stock has a fifty day moving average of $28.52 and a 200-day moving average of $29.57. The firm has a market capitalization of $1.25 billion, a PE ratio of 33.27 and a beta of 0.76. The company has a quick ratio of 4.17, a current ratio of 5.24 and a debt-to-equity ratio of 0.59.

Insider Buying and Selling

In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of the company's stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the sale, the director now owns 140,384 shares in the company, valued at approximately $4,165,193.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the transaction, the director now owns 22,127 shares in the company, valued at approximately $677,086.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gary W. Pace sold 1,066 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total value of $31,628.22. Following the transaction, the director now owns 140,384 shares in the company, valued at approximately $4,165,193.28. The disclosure for this sale can be found here. 6.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PCRX. HC Wainwright reaffirmed a "buy" rating and issued a $57.00 price objective on shares of Pacira BioSciences in a research note on Monday, March 4th. Needham & Company LLC reissued a "buy" rating and set a $45.00 price target on shares of Pacira BioSciences in a research report on Tuesday, April 9th. JPMorgan Chase & Co. started coverage on shares of Pacira BioSciences in a research report on Thursday, March 7th. They set an "overweight" rating and a $45.00 price target for the company. TheStreet raised shares of Pacira BioSciences from a "d+" rating to a "c" rating in a research report on Thursday, February 29th. Finally, Royal Bank of Canada decreased their price target on shares of Pacira BioSciences from $53.00 to $45.00 and set an "outperform" rating for the company in a research report on Friday, March 1st. Eleven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Pacira BioSciences presently has a consensus rating of "Buy" and a consensus target price of $49.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.